|
Patent landscape, scope, and claims: |
United States Drug Patent 7,951,958: Scope, Claims, and Landscape Analysis
Summary
United States Patent 7,951,958, titled "2-AROYLPHENYLIMIDAZOLES AND DERIVATIVES AS MODULATORS OF 2-ARACHIDONYLGLYCEROL HYDROLASE (FAAH)," issued on May 31, 2011, to Prosidion Healthcare Limited. The patent claims a class of chemical compounds, specifically 2-aroylphenylimidazoles and their derivatives, designed to modulate the activity of fatty acid amide hydrolase (FAAH). FAAH is an enzyme involved in the hydrolysis of endocannabinoids, which are lipid-based signaling molecules in the body. Inhibition of FAAH can lead to increased levels of endocannabinoids, which are implicated in various physiological processes, including pain, inflammation, anxiety, and appetite regulation. The patent's claims define the scope of the protected invention through specific structural features of the claimed compounds and their therapeutic applications. Analysis of the patent landscape surrounding this patent reveals ongoing research and development in the FAAH inhibitor space, with potential implications for new therapeutic agents.
What is the Core Invention Claimed in US Patent 7,951,958?
The patent protects a genus of chemical compounds characterized by a specific molecular structure, intended for the therapeutic modulation of FAAH. The primary claims define these compounds and their use in treating various conditions.
What are the Key Structural Features of the Claimed Compounds?
The patent defines the claimed compounds through Markush claims, allowing for a range of substituents and variations within a defined core structure.
- Core Structure: The central structural motif is a 2-aroylphenylimidazole. This implies a phenyl ring substituted with an aroyl group (an acyl group derived from an aromatic acid) and an imidazole ring.
- Substituents: The claims detail various permissible substituents on different parts of this core structure, including the phenyl ring, the aroyl group, and the imidazole ring. These substituents are denoted by variables (e.g., R1, R2, R3) which can represent specific atoms or groups of atoms, such as alkyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, amino, or hydroxyl groups.
- Specific Examples: The patent provides numerous specific exemplified compounds that fall within the scope of the broader claims. These examples illustrate concrete chemical entities believed to embody the invention. For instance, a typical exemplified compound might be identified by a chemical name or a structure diagram.
What are the Asserted Therapeutic Uses of These Compounds?
The patent claims the use of these compounds for treating or preventing medical conditions mediated by FAAH.
- Mechanism of Action: The compounds are designed to inhibit FAAH, thereby increasing the endogenous levels of fatty acid amides, such as anandamide.
- Therapeutic Areas: The claimed therapeutic applications are broad and include:
- Pain management, including chronic pain and neuropathic pain.
- Inflammation and inflammatory conditions.
- Anxiety disorders and other central nervous system conditions.
- Conditions involving appetite regulation.
- Other diseases or disorders where modulation of endocannabinoid signaling is beneficial.
How is the Scope of Protection Defined by the Patent Claims?
The claims of US Patent 7,951,958 precisely delineate the boundaries of the intellectual property protected. They are structured to cover a broad class of related compounds while also specifying particular embodiments.
What are the Independent Claims of the Patent?
Independent claims define the invention without reference to other claims. They typically encompass the broadest scope of protection.
- Claim 1: This is a primary independent claim. It defines a compound of a specific general formula (Formula I), which represents the 2-aroylphenylimidazole core with defined variable substituents (R1 to R7). The claim specifies that the compound is useful for modulating FAAH activity. The formula details various options for each substituent, such as alkyl, cycloalkyl, aryl, heteroaryl, halo, alkoxy, amino, and hydroxyl groups, and their positions on the core structure. For example, R1 might be an alkyl group, R2 might be hydrogen or a halogen, and R3 could be a substituted phenyl ring.
- Claim 15: This independent claim focuses on a pharmaceutical composition. It claims a composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation aspect of the invention.
- Claim 16: This independent claim asserts a method of treating a disease. It claims a method of treating a condition mediated by FAAH in a subject, comprising administering a therapeutically effective amount of a compound of Claim 1.
What are the Dependent Claims and How Do They Narrow the Scope?
Dependent claims refer back to previous claims (either independent or other dependent claims) and add further limitations or specific embodiments. They provide narrower, more specific protection within the scope of the parent claim.
- Examples of Limitations: Dependent claims might specify particular chemical groups for the variables (e.g., "a compound of claim 1, wherein R1 is a methyl group"), limit the compound to a specific stereoisomer, or define a particular salt or solvate form.
- Further Embodiments: They can also define specific uses (e.g., "a compound of claim 1 for use in treating pain") or particular pharmaceutical compositions (e.g., "a pharmaceutical composition of claim 15, further comprising an anti-inflammatory agent").
- Specific Compound Claims: Many dependent claims will define specific, named compounds that fall within the broader genus of Claim 1, offering protection for concrete drug candidates.
What is the Patent Landscape Surrounding US Patent 7,951,958?
The patent landscape for FAAH inhibitors is competitive, reflecting significant research interest in this therapeutic area. US Patent 7,951,958 is situated within a broader ecosystem of patents covering similar compounds, mechanisms, and applications.
Who are the Key Players in the FAAH Inhibitor Patent Space?
Several pharmaceutical companies and research institutions hold patents related to FAAH inhibitors.
- Prosidion Healthcare Limited: The assignee of US Patent 7,951,958.
- Other Major Players: Companies like Johnson & Johnson, Pfizer, Merck, and smaller biotechnology firms have also actively patented compounds and technologies in the FAAH inhibitor space.
- Academic Institutions: Universities are also sources of early-stage research and patent filings, often licensed to pharmaceutical companies.
What are the Overlapping Technologies and Potential Infringement Concerns?
Patents in this field often share common structural motifs or therapeutic targets, creating a complex web of intellectual property.
- Structural Similarities: Other patents may claim compounds with similar core structures or functional groups to those claimed in US Patent 7,951,958, potentially leading to infringement issues.
- Mechanism of Action Overlap: Patents covering different chemical classes that achieve FAAH inhibition, or patents claiming the therapeutic uses of FAAH inhibitors broadly, can also create interference.
- Freedom to Operate (FTO): Companies developing new FAAH inhibitors must conduct thorough FTO analyses to ensure their products do not infringe existing patents, including US Patent 7,951,958. This involves scrutinizing the claims of relevant patents against the structure and intended use of the new compound.
What is the Status of Key Patents in the FAAH Inhibitor Field?
Many foundational patents in this area are nearing or have passed their expiration dates. However, newer patents continue to be filed, covering novel compounds, formulations, and uses.
- Patent Term: US patents granted before June 8, 1995, have a term of 20 years from the filing date. Patents filed on or after June 8, 1995, have a term of 20 years from the filing date, subject to potential extensions for patent term restoration (e.g., due to regulatory review delays) or adjustments. US Patent 7,951,958 was filed on January 14, 2005, and granted on May 31, 2011. Its term would have expired around January 14, 2025, barring any extensions.
- Ongoing Innovation: Despite patent expirations, companies continue to innovate by developing next-generation FAAH inhibitors with improved efficacy, safety profiles, or targeting specific disease subtypes. These efforts result in new patent filings that extend the IP protection in the field.
What are the Specific Compound Examples Provided in the Patent?
The patent provides a substantial list of specific chemical compounds that embody the invention. These are often presented in tables with chemical names, structures, and sometimes biological data.
How are these Examples Organized and Presented?
The patent typically includes sections detailing "Examples" or "Experimental Examples."
- Synthesis Procedures: For each exemplified compound, the patent describes the synthetic route used to prepare it, including reagents, reaction conditions, and purification methods.
- Characterization Data: Analytical data such as Nuclear Magnetic Resonance (NMR) spectroscopy, Mass Spectrometry (MS), and High-Performance Liquid Chromatography (HPLC) are provided to confirm the identity and purity of the synthesized compounds.
- Biological Assays: The patent may also present in vitro and in vivo data demonstrating the FAAH inhibitory activity of the exemplified compounds, often including IC50 values (the concentration of the compound required to inhibit 50% of the enzyme's activity).
What is the Significance of these Specific Examples?
These specific examples serve multiple purposes:
- Demonstrate Utility: They provide concrete evidence that the claimed invention is not merely theoretical but can be practically realized.
- Support Broad Claims: They help to support the validity of the broad Markush claims by demonstrating that compounds falling within the claimed genus are indeed achievable and possess the desired activity.
- Illustrate Embodiments: They highlight specific drug candidates that Prosidion Healthcare Limited or its licensees could pursue for development.
Key Takeaways
- US Patent 7,951,958 protects a class of 2-aroylphenylimidazole compounds as FAAH inhibitors.
- The patent's claims define a broad genus of compounds with specific structural requirements and outline their therapeutic applications in pain, inflammation, and CNS disorders.
- The patent landscape for FAAH inhibitors is active, with multiple entities holding relevant intellectual property.
- Companies developing FAAH inhibitors must conduct thorough freedom-to-operate analyses to navigate existing patent rights.
- While the patent term for US 7,951,958 has largely expired, it forms part of the foundational IP in the FAAH inhibitor field.
Frequently Asked Questions
-
What is the expiration date of US Patent 7,951,958?
The patent was filed on January 14, 2005, and granted on May 31, 2011. Under standard patent law, its term is 20 years from the filing date, meaning it likely expired around January 14, 2025, barring any Patent Term Extensions.
-
Can generic manufacturers produce compounds covered by US Patent 7,951,958 now?
If the patent term has expired and there are no other overlapping patents or regulatory exclusivities (such as New Chemical Entity exclusivity), generic manufacturers may be able to produce compounds falling within the patent's claims. However, specific market exclusivity for a drug product based on these compounds would need separate evaluation.
-
What are the main therapeutic areas targeted by the compounds in this patent?
The patent claims therapeutic uses in conditions mediated by FAAH, primarily including pain (chronic and neuropathic), inflammation, anxiety disorders, and conditions related to appetite regulation.
-
Are there any currently marketed drugs based on the compounds claimed in this patent?
A thorough review of marketed drugs and their underlying patent portfolios is required to definitively answer this. However, the patent's issuance date and subsequent term expiration suggest that any products developed directly from this patent would likely be facing or have faced generic competition if they reached market.
-
What does "modulators of 2-arachidonoylglycerol hydrolase (FAAH)" mean in the context of this patent?
It means the compounds are designed to affect the activity of the FAAH enzyme. Specifically, the patent aims to develop inhibitors of FAAH, which prevent the breakdown of endocannabinoids like anandamide and 2-arachidonoylglycerol (2-AG) in the body, thereby increasing their levels and eliciting therapeutic effects.
Citations
[1] Prosidion Healthcare Limited. (2011). 2-AROYLPHENYLIMIDAZOLES AND DERIVATIVES AS MODULATORS OF 2-ARACHIDONYLGLYCEROL HYDROLASE (FAAH) (U.S. Patent No. 7,951,958). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
